[Pharmaco-ethological analysis of agonistic behavior between resident and intruder mice: effects of adrenergic beta-blockers]. 1985

H Yoshimura, and N Ogawa

The present study was conducted to investigate the effects of adrenergic beta-blockers on agonistic behavior using quantitative ethological methods. In order to generate the agonistic behavior we employed the resident-intruder paradigm: An intruder male mouse is introduced into the home cage of a resident male mouse that has been cohabiting with a female for 5 weeks. The following drugs were administered orally to either resident or intruder mice: dl-Propranolol, oxprenolol, and carteolol. The injection-test interval was 60 min. Each test was recorded using a video TV monitor system, and at a later time several behavioral elements shown by both resident and intruder mice were measured. dl-Propranolol (5, 10, 20 mg/kg), oxprenolol (30, 50, 75 mg/kg), and carteolol (30, 50, 75 mg/kg) significantly suppressed the resident's aggressive episodes (offensive sideways posture, tail rattle, and attack bite) when resident mice were treated. By contrast, when intruder mice were treated with beta-blockers, aggressive episodes by untreated residents were not affected. The results suggest that dl-propranolol, oxprenolol, and carteolol have specific effects on the hostility of resident mice.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010096 Oxprenolol A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. Coretal,Koretal,Oxprenolol Hydrochloride,Slow Trasicor,Tevacor,Trasicor,Hydrochloride, Oxprenolol,Trasicor, Slow
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002354 Carteolol A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol Hydrochloride,Carteolol Monohydrochloride,OPC-1085,Hydrochloride, Carteolol,Monohydrochloride, Carteolol,OPC 1085,OPC1085
D004924 Escape Reaction Innate response elicited by sensory stimuli associated with a threatening situation, or actual confrontation with an enemy. Flight Reaction,Escape Reactions,Flight Reactions,Reaction, Escape,Reaction, Flight,Reactions, Escape,Reactions, Flight
D005260 Female Females
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

H Yoshimura, and N Ogawa
January 1984, Progress in clinical and biological research,
H Yoshimura, and N Ogawa
September 1986, Pharmacology, biochemistry, and behavior,
H Yoshimura, and N Ogawa
January 1981, Pharmacology, biochemistry, and behavior,
H Yoshimura, and N Ogawa
January 1984, Progress in clinical and biological research,
H Yoshimura, and N Ogawa
December 1984, Biulleten' eksperimental'noi biologii i meditsiny,
H Yoshimura, and N Ogawa
April 1987, The American journal of psychiatry,
H Yoshimura, and N Ogawa
January 1990, Blood vessels,
H Yoshimura, and N Ogawa
January 2007, Current medicinal chemistry,
H Yoshimura, and N Ogawa
April 1985, The Australasian journal of dermatology,
H Yoshimura, and N Ogawa
November 1976, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!